Parkinson’s Active Immunotherapy Medicine Phase 1 Study Positive Results Published

Vaxxinity, Inc. announced today that the journal Nature Medicine has published groundbreaking exploratory data from the Company's Phase 1 clinical trial of UB-312 in patients with Parkinson's disease (PD).

The Phase 1 successfully met its primary outcome measures, demonstrating that UB-312 was generally well-tolerated and induced anti-aggregated α-synuclein (αSyn) antibody responses in healthy volunteers and PD patients. Specifically, 12 of 13 PD patients who completed dosing developed anti-αSyn antibodies.

And UB-312-induced antibodies significantly decreased levels of αSyn, a key pathology in PD and other synucleinopathies. This suggests that UB-312 can help to eliminate the buildup of harmful, toxic forms of the protein αSyn in the brain.

Furthermore, patients with detectable UB-312-induced antibodies in cerebrospinal fluid exhibited significant improvement in motor experiences of daily living as measured by the MDS-UPDRS Part II, a commonly accepted clinical scale.

This announcement marks a potentially significant milestone in pursuing innovative PD care.

"UB-312 has the potential to become an important and potent disease-modifying therapy for Parkinson's disease. It would be truly amazing if we could vaccinate people against Parkinson's disease in the future!" said Professor Geert Jan Groeneveld, neurologist and principal investigator of the Phase 1 clinical trial performed at the Centre for Human Drug Research in Leiden, the Netherlands, in a press release on June 20, 2024.

Parkinson's disease, a progressive neurodegenerative condition, currently lacks an approved disease-modifying treatment. Alpha-synuclein, a key protein in PD pathology, forms aggregates known as Lewy bodies that contribute to neuronal degeneration.

This active immunotherapy medicines research was funded by the Michael J. Fox Foundation, assessing target engagement in collaboration with the Mayo Clinic and UTHealth Houston in Texas.